Chemistry:Alogabat
From HandWiki
Alogabat (INN, USAN; developmental code names RG-7816 and RO7017773) is an α5 subunit-containing GABAA receptor positive allosteric modulator which is under development for the treatment of pervasive developmental disorders (e.g., autism) and Angelman syndrome.[1][2][3][4] It is taken by mouth.[1]
As of June 2024, alogabat is in phase 2 clinical trials for pervasive developmental disorders and Angelman syndrome.[1][2] It is under development by Roche.[1][2]
See also
References
- ↑ 1.0 1.1 1.2 1.3 "Alogabat - Genentech". 28 June 2024. https://adisinsight.springer.com/drugs/800051895.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on RG-7816 with Synapse". 19 September 2024. https://synapse.patsnap.com/drug/dae52e84cedb4f95a10bc8ae9f919293.
- ↑ "Subtype Selective γ-Aminobutyric Acid Type A Receptor (GABAAR) Modulators Acting at the Benzodiazepine Binding Site: An Update". Journal of Medicinal Chemistry 63 (7): 3425–3446. April 2020. doi:10.1021/acs.jmedchem.9b01312. PMID 31738537.
- ↑ "Ion Channels as Targets in Drug Discovery: Outlook and Perspectives". Ion Channels as Targets in Drug Discovery. Cham: Springer International Publishing. 2024. p. 1–34. doi:10.1007/978-3-031-52197-3_1. ISBN 978-3-031-52196-6.
 |  |
